Study links Actos with delayed dementia

Share this article:

Diabetes medication Actos could be repurposed for Alzheimer's disease. Reuters reports that a clinical trial indicates that the “cheap generic treatment” appears to be associated with delayed onset of the memory-eating disease.

Reuters notes that earlier studies indicated this may be a potential benefit, but this latest trial was a heftier effort, based on German healthcare data from 2004 through 2010 across a data set that included 146,000 patients ages 60 and older who did not initially show signs of dementia.

Researchers found that 13,841 patients eventually suffered dementia but the risk was reduced for every three months patients took Actos.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.